The pursuit of oncotargets through understanding defective cell regulation

Meng Qiao; Qian Shi; Arthur B. Pardee

doi:10.18632/oncotarget.189

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

The pursuit of oncotargets through understanding defective cell regulation

Meng Qiao, Qian Shi _ and Arthur B. Pardee

PDF | HTML | How to cite

Oncotarget. 2010; 1:544-551. https://doi.org/10.18632/oncotarget.189

Metrics: PDF 2453 views | HTML 3057 views | ?

Abstract

Received: April 29, 2010, Accepted: October 18, 2010, Published: October 18, 2010

More effective anticancer agents are essential, as has too often been demonstrated by the paucity of therapeutics which preserve life. Their discovery is very difficult. Many approaches are being applied, from testing folk medicines to automated high throughput screening of large chemical libraries. Mutations in cancer cells create dysfunctional regulatory systems. This Perspective summarizes an approach to applying defective molecular control mechanisms as oncotargets on which drug discoveries against cancer can be based.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 189

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

The pursuit of oncotargets through understanding defective cell regulation

Abstract